Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that low-dose oral minoxidil is generally safe for treating various types of hair loss, though it may cause hypertrichosis and pedal edema, especially at higher doses.

This study found that low doses of bisphenol A may increase proliferation of the ventral prostate in adult rats by altering the estrogen to androgen ratio and gene expression.

This study reviewed adverse events associated with low-dose oral minoxidil for treating alopecia, finding hypertrichosis and fluid retention as common, typically manageable side effects without needing treatment discontinuation.

This review discusses the potential of low-dose oral minoxidil as a safe and effective treatment for certain hair disorders, including alopecia, but reports no new clinical results.

This study reported that once-daily treatment with oral minoxidil and spironolactone for 12 months reduced hair loss severity and hair shedding in women with pattern hair loss, with generally mild side effects, though results came from an uncontrolled, observational pilot study.

This study evaluated the effectiveness and safety of low-dose oral minoxidil (2.5-5 mg daily) in men with male androgenetic alopecia, aiming to contribute data to an area with limited previous reports. Results are not provided in the abstract.

In this study, low-dose oral minoxidil for hair loss was associated with infrequent systemic adverse effects, and only 1.7% of patients discontinued treatment due to these effects.

Low-dose oral minoxidil effectively treats female hair loss with good safety.

In this study, researchers found no evidence of increased prevalence of pericardial effusions in alopecia patients treated with low-dose oral minoxidil compared to those not receiving minoxidil, based on point-of-care ultrasound evaluations.

This research letter reports that low-dose oral minoxidil improved hair density and length in children with loose anagen hair syndrome.

This letter discusses the limited adaptation of low dose oral minoxidil for androgenetic alopecia in North America and reports no new clinical results; the authors suggest safety concerns or unclear dosing may be factors.

This study observed eyebrow regrowth in 7 patients with frontal fibrosing alopecia treated with low-dose oral minoxidil, suggesting it may be a promising treatment option, especially in early disease stages.

This article describes the characteristics and management of hypertrichosis induced by low-dose oral minoxidil used for hair disorders, but reports no new clinical findings.

In this study, low-dose oral minoxidil was found to improve hair density in 80% of pediatric patients with androgenetic alopecia or telogen effluvium, with mild side effects primarily reported.

This letter discusses adverse events related to low-dose oral minoxidil for alopecia, highlighting age-related risks and stressing the importance of contraindication awareness with no new clinical results presented.

Low-dose oral minoxidil does not cause tachycardia in hair loss patients.

This case report describes a patient with permanent chemotherapy-induced alopecia who experienced full hair regrowth after treatment with low-dose oral minoxidil.

This study found that 1 mg/day low-dose oral minoxidil significantly increased hair count compared to 0.25 mg/day over 24 weeks in women with female pattern hair loss, though no differences were observed in hair-shedding and quality-of-life scores between the two doses.

In this correspondence, researchers reported that very-low-dose oral minoxidil (0.25 mg/d) showed some effectiveness in stabilizing trichoscopic parameters in male androgenetic alopecia. However, their analysis suggests that higher doses (2.5–5 mg/d) may lead to better clinical responses with similar rates of adverse events.

Low-dose oral minoxidil can cause dizziness in women without lowering blood pressure, so careful monitoring is needed.

Low-dose oral minoxidil combined with topical minoxidil improves hair density in breast cancer patients but may cause excess hair growth.

This study aims to evaluate the efficacy and safety of combining low-dose oral minoxidil with spironolactone for treating female androgenetic alopecia, amid concerns about potential blood pressure effects, though the results are not reported here.

In this study, researchers aimed to evaluate the safety and tolerability of low-dose oral minoxidil in adolescents, as existing data on its use in this population are limited and there are no specific pediatric guidelines for prescribing it. Results are not reported.

This study found that for people with androgenetic alopecia, increasing the dosage of low-dose oral minoxidil is associated with improvements in hair diameter and density, but also raises the risk of hypertrichosis and cardiovascular adverse events.

This pilot study found that among male androgenetic alopecia patients, 2.5 mg oral minoxidil with platelet-rich plasma led to higher patient satisfaction than 1.25 mg, though hair count improvements were not statistically significant.

This study highlights the complex clinical issues associated with using low dose oral minoxidil for alopecia, emphasizing the need for careful cardiology-dermatology collaboration due to rare but serious cardiovascular risks, especially in patients with existing cardiorenal or cardiovascular concerns.

This report highlights a serious complication associated with low-dose oral minoxidil in treating female androgenetic alopecia, an adverse effect previously thought to be rare and minor.

In this study, low-dose oral minoxidil for androgenetic alopecia was generally safe, showing small average changes in blood pressure and heart rate with infrequent cardiovascular issues, though monitoring is essential, especially in patients with conditions like hypertension or arrhythmias.